DUBLIN--(BUSINESS WIRE)--The "Global Viral and Non-Viral Vector Manufacturing Market: Focus on Vector Type, Application, Disease and Region - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
The advent of advanced therapies, including gene therapy and cell therapy, which employ the use of vectors, has created a huge impact in the field of medicine in the past few decades. Therapies that require genetic modification, including the introduction of therapeutic deoxyribonucleic acid (DNA)/gene into a patient's body or cell, demonstrated tremendous potential for treating several fatal diseases, including cancer, Alzheimer's disease, Parkinson's disease, and rheumatoid arthritis, among others. Promising results displayed by these vector-based therapies in several preclinical and clinical studies have further emphasized the development and standardization of various viral and non-viral vectors to address unmet medical needs.
The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020 and is expected to reach $27.03 billion by 2031, witnessing a CAGR of 18.54% during the forecast period 2021-2031.
Known to reduce the cost of treatment and help decrease repeated administration of medications, viral vectors, and non-viral vectors have gained significant attention globally as a novel therapeutic approach for treating various critical diseases, thereby promoting a surge of investments in drug development and commercialization.
Growing prominence of gene and cell therapy products (that utilize vectors) and increasing funding activities driving research related to vector-based therapies are the key driving factors fueling the growth of the global viral and non-viral vector manufacturing market. Moreover, rising incidences of genetic disorders, cancers, and infectious diseases, coupled with the increasing number of clinical studies and robust pipeline of gene and cell therapy products as well as vector-based vaccines, are the additional driving factors encouraging market growth.
Market Report Coverage - Viral and Non-Viral Vector Manufacturing
Market Segmentation
- Vector Type - Viral Vector and Non-Viral Vector
- Disease - Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases
- Application - Gene Therapy, Vaccinology, Cell Therapy, and Other Applications
Market Growth Drivers
- Rapid Uptake of Viral Vector to Develop Innovative Therapies
- Increasing Number of Clinical Studies for the Development of Gene Therapy
- Favorable Funding Scenario for Vector-Based Therapies
- Increasing Adoption of Nucleic Acid Therapeutics
- Rise in Synergistic Activities in the Market
Market Challenges
- Unaffordable Cost of Gene Therapy
- High Manufacturing Cost of Viral Vectors
- Complications Associated with Large-Scale Production of Viral Vectors
- Low Transfection Efficiency
Market Opportunities
- Rise in Demand for Synthetic Genes
- Emergence of Next-Generation Vectors
- Limitation of Viral Vectors
Key Companies Profiled
Boehringer Ingelheim, Catalent, Inc., FUJIFILM Holdings Corporation, Danaher Corporation, Genscript Biotech Corporation, Lonza Group AG, Merck KGaA Inc., Oxford Biomedica plc, Sartorius AG, Takara Bio Inc., Thermo Fisher Scientific Inc., Wuxi AppTec, Acuitas Therapeutics, Evonik Industries AG, Exelead, Inc., Entos Pharmaceuticals, Genevant Sciences GmbH, T&T Scientific Corporation, Moderna, Inc., CureVac N.V.
Key Questions Answered in this Report:
- What are the major advancements in viral and non-viral vector manufacturing? What are the key trends of the global viral and non-viral vector manufacturing market?
- What are the major drivers, challenges, and opportunities of the global viral and non-viral vector manufacturing market?
- What are the key developmental strategies implemented by the key players of the global viral and non-viral vector manufacturing market to sustain the competition of the market?
- What is the regulatory scenario of the global viral and non-viral vector manufacturing market? What are the initiatives implemented by different governmental bodies and guidelines put forward to regulate the commercialization of viral and non-viral vector manufacturing products?
- What are major milestones in patenting activity in the global viral and non-viral vector manufacturing market?
- What was the market size of the global viral and non-viral vector manufacturing market in 2020, and what is the market size anticipated to be by 2031? What is the expected growth rate of the global viral and non-viral vector manufacturing market during the forecast period 2021-2031?
- What is the global market size for manufacturing different types of viral and non-viral vectors available in the global viral and non-viral vector manufacturing market? What are the key trends of the market with respect to different vectors, and which vector type is expected to dominate the market in 2031?
- What are the different disease areas where non-viral vectors and viral vectors are employed in the global viral and non-viral vector manufacturing market? Which disease type dominated the market in 2020 and is expected to dominate in 2031?
- What are the different applications associated with the viral vector and non-viral vector manufacturing? What was the contribution of each of the application areas in the global viral and non-viral vector manufacturing market in 2020, and what is it expected in 2031?
For more information about this report visit https://www.researchandmarkets.com/r/mt4xjf
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
